The RAPID and RAPID Open Label Extension (RAPID-OLE) studies represent the largest multicenter randomized placebo-controlled trials conducted on this therapy
A recurring practical problem in DSIP research is pharmacokinetics
The results showed that the chemiluminescence intensity at the tumor site gradually weakened or even disappeared with the progression of NP4 treatment, while the chemiluminescence intensity in mice without drug treatment and those treated with Ru(II)-OH and NP2 gradually increased
Read review Dihexa for Endometriosis Brain Fog The November 2025 Lancet O&G/WH 'overlooked symptom' commentary from Edinburgh EXPPECT, the April 2025 Horn FACT-Cog 1,239-patient survey (~80% perceived cognitive impairment), the March 2025 NICE TA1057 Ryeqo approval (first daily pill on NHS), the April 2024 NICE NG73 update, the April 2026 renewed Womens Health Strategy with 117 action points, the 2023 Greaves CNS-wide glial activation mouse model, the BDNF/TrkB central-sensitisation directionality paradox, and the ~1.5 million UK women affected
As Yaribeygi, Journal of Cellular Physiology emphasized, while mitochondrial peptides hold therapeutic promise, their systemic effects require caution due to the lack of long-term human studies
Oxidized Low-Density Lipoprotein Contributes to Atherogenesis via Co-Activation of Macrophages and Mast Cells. PloS One, vol
